Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies
Clinical trial NCT05609942 · TERMINATED
Trial details
- NCT number
- NCT05609942
- Sponsor
- Blueprint Medicines Corporation
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-25
- Primary completion
- 2025-01-14
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.